Citigroup Inc Pulse Biosciences, Inc. Transaction History

Citigroup Inc

$190 Billion
Q1 2025

A detailed history of Citigroup Inc transactions in Pulse Biosciences, Inc. stock. As of the latest transaction made, Citigroup Inc holds 13,847 shares of PLSE stock, worth $205,489. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,847

Previous 15,591 11.19%

Holding current value

$205,489

Previous $288,000 22.92%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$15.61 - $24.56 $27,223 - $42,832	-1,744 Reduced 11.19%	13,847 $222,000
Q4 2024 Feb 12, 2025	BUY	$14.56 - $21.08 $34,638 - $50,149	2,379 Added 18.01%	15,591 $288,000
Q3 2024 Nov 12, 2024	BUY	$10.83 - $21.83 $99,895 - $201,359	9,224 Added 231.29%	13,212 $231,000
Q2 2024 Aug 12, 2024	BUY	$6.69 - $14.54 $7,011 - $15,237	1,048 Added 35.65%	3,988 $44,000
Q1 2024 May 10, 2024	BUY	$7.8 - $11.02 $4,797 - $6,777	615 Added 26.45%	2,940 $25,000
Q4 2023 Feb 09, 2024	BUY	$3.85 - $12.84 $8,924 - $29,763	2,318 Added 33114.29%	2,325 $28,000
Q3 2023 Nov 09, 2023	SELL	$4.03 - $8.73 $19,356 - $41,930	-4,803 Reduced 99.85%	7 $0
Q2 2023 Aug 10, 2023	BUY	$3.67 - $8.64 $17,652 - $41,558	4,810 New	4,810 $34,000
Q3 2022 Nov 10, 2022	BUY	$1.23 - $2.3 $5,382 - $10,064	4,376 Added 3529.03%	4,500 $10,000
Q2 2022 Aug 10, 2022	SELL	$1.48 - $4.28 $557 - $1,613	-377 Reduced 75.25%	124 $0
Q1 2022 May 12, 2022	SELL	$4.21 - $14.79 $13,328 - $46,825	-3,166 Reduced 86.34%	501 $2,000
Q4 2021 Feb 10, 2022	BUY	$14.78 - $24.4 $29,116 - $48,068	1,970 Added 116.09%	3,667 $54,000
Q3 2021 Nov 10, 2021	BUY	$17.25 - $26.63 $29,273 - $45,191	1,697 New	1,697 $36,000

Others Institutions Holding PLSE

# of Institutions

Shares Held

5.55M

Call Options Held

76.1K

Put Options Held

60.8K

View Full List

About Pulse Biosciences, Inc.

Ticker PLSE
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 37,125,900
Market Cap $551M
Description
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using it...

More about PLSE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account